These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8678507)

  • 21. [Problems in conducting clinical trials for cancer patients].
    Kondo M
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):151-5. PubMed ID: 8611042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reform of Japan's NTP and its technical perspectives].
    Mori T
    Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
    Zon R; Meropol NJ; Catalano RB; Schilsky RL
    J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. End points in cancer clinical trials and the drug approval process.
    Schilsky RL
    Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Post launch studies].
    Akaza H; Ohashi Y; Shimada Y; Ikeda T; Saijo N; Isonishi S; Hirao Y; Tsuruo T; Tsukagoshi S; Sone S; Nakamura S; Kato M; Mikami O; von Euler M; Blackledge G; Milsted B; Vose B
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):2037-48. PubMed ID: 12465411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Closing Remarks.
    Reed E
    Oncologist; 1996; 1(4):276-277. PubMed ID: 10388002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Improving the infrastructure for clinical trials in Japan].
    Nakano S
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):225-30. PubMed ID: 9987523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trials and approval of anti-cancer agents.
    Iwasaki M; Hinotsu S; Katsura J
    Jpn J Clin Oncol; 2010 Sep; 40 Suppl 1():i65-69. PubMed ID: 20870922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
    Jaillon P
    Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [How to plan and execute multinational clinical studies properly-management of ethnic differences, private information, and genetic testing].
    Iwasaki M
    Gan To Kagaku Ryoho; 2010 May; 37(5):771-6. PubMed ID: 20495304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al.
    Smith MA; Anderson BD
    Eur J Cancer; 2004 Aug; 40(12):1893-5. PubMed ID: 15288292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trials in the new millennium.
    DeMets DL
    Stat Med; 2002 Oct; 21(19):2779-87. PubMed ID: 12325093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New drugs in early clinical trials and drug resistance--US-Japan joint seminar].
    Ogawa M
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):697-700. PubMed ID: 2321989
    [No Abstract]   [Full Text] [Related]  

  • 38. [Insights into neurological drug development in Japan].
    Nakamura H; Uyama Y
    Brain Nerve; 2012 Mar; 64(3):229-35. PubMed ID: 22402716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations.
    Natl Cancer Inst Monogr; 1980 Dec; (55):1-179. PubMed ID: 7010179
    [No Abstract]   [Full Text] [Related]  

  • 40. [Contribution of Japan to develop new anticancer agents].
    Sajjo N
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):242-6. PubMed ID: 8611054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.